Discontinued — last reported Q1 '18
Kenvue Allowance for Doubtful Accounts Receivable (Current) decreased by 26.9% to $19.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 20.8%, from $24.00M to $19.00M. Over 3 years (FY 2022 to FY 2025), Allowance for Doubtful Accounts Receivable (Current) shows a downward trend with a -9.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
A significant increase relative to receivables may signal deteriorating customer credit quality or economic headwinds in specific markets.
This is a contra-asset account representing the estimated amount of accounts receivable that the company expects will no...
Standard across all industries; peers in the medical device sector typically maintain low levels unless operating in high-risk emerging markets.
allowance_for_doubtful_accounts_receivable_current| Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $35.00M | $38.00M | $29.00M | $27.00M | $25.00M | $26.00M | $25.00M | $26.00M | $26.00M | $24.00M | $25.00M | $25.00M | $26.00M | $19.00M |
| QoQ Change | — | +8.6% | -23.7% | -6.9% | -7.4% | +4.0% | -3.8% | +4.0% | +0.0% | -7.7% | +4.2% | +0.0% | +4.0% | -26.9% |
| YoY Change | — | — | — | — | -28.6% | -31.6% | -13.8% | -3.7% | +4.0% | -7.7% | +0.0% | -3.8% | +0.0% | -20.8% |